GALAPAGOS NV

Business Model and Scope

At the cutoff, Galapagos was no longer the diversified research and commercial biotechnology company visible in much of the five-year history. It had transferred the Jyseleca business to Alfasigma in January 2024, stopped small-molecule discovery in January 2025, abandoned a proposed corporate separation in May 2025, and initiated the wind-down of its cell-therapy activities in January 2026 after consultation processes. The cell-therapy closure was expected to affect about 365 employees across Europe, the United States, and China and to be substantially complete by the end of the third quarter of 2026.

The surviving economic perimeter consisted principally of cash and financial investments, the development-stage TYK2 inhibitor GLPG3667, residual contractual rights and obligations, and a plan to acquire, license, or otherwise invest in new product candidates. Following the cell-therapy wind-down, GLPG3667 would be the only product candidate in development until another asset is acquired or developed. Ongoing Jyseleca royalties and possible earn-outs from Alfasigma may produce cash, but the company no longer controls that commercial business. Cell-therapy programs subject to wind-down are not a continuing platform merely because their historical expenses and data appear in the filings.

This is therefore an asset-selection and clinical-development enterprise, not an established drug franchise. Its operating identity depends on transactions that had not occurred by the cutoff. The proposed Lakefront name reflects that new direction; it does not create new economics or sever the reporting history.

Customers and Purchasing Decisions

There is no meaningful current product customer in the ordinary commercial sense. If GLPG3667 or a future acquired candidate reaches the market, patients and physicians will choose based on efficacy, safety, convenience, durability, and fit within treatment practice. Hospitals, specialty pharmacies, insurers, pharmacy-benefit managers, and government payers will influence access and net price. Regulators are gatekeepers rather than customers, but their evidence requirements determine whether any sale is legally possible.

Before commercialization, the company's immediate counterparties are asset owners, biotechnology companies, universities, research organizations, investigators, and potential pharmaceutical partners. An asset seller values price, development competence, speed, future milestones, royalties, and confidence that the buyer can finance trials. Galapagos brings liquidity and some clinical-development experience, but sellers can negotiate with many pharmaceutical and biotechnology buyers. Competition for differentiated, clinically de-risked programs can transfer much of the expected value to the seller before Galapagos assumes development risk.

If the company partners a program, bargaining power depends on data quality, patent life, development stage, competing bids, and each party's funding and commercial capabilities. Gilead remains an important shareholder and contractual counterparty, not a captive customer. Alfasigma controls Jyseleca economics after the transfer, while Galapagos retains specified royalty and contingent-payment exposure. Patients may ultimately benefit most from a successful therapy; payers may capture part of the value through reimbursement negotiation; licensors and partners may capture substantial economics through upfront payments, milestones, and royalties.

Profit Creation and Value Capture

The company did not have a repeatable operating profit engine at the cutoff. Biopharmaceutical profit would require a causal sequence: acquire or discover an asset at a cost below its risk-adjusted value; design and execute trials that establish a clinically meaningful benefit; obtain regulatory approval; secure reimbursement and physician adoption; and retain enough product rights, milestones, or royalties after development, manufacturing, commercialization, and partner claims. Failure at any stage can make the preceding expenditure unrecoverable.

Fiscal 2025 accounting profit should not be mistaken for that sequence. Total net revenue was €1.112 billion, but €1.069 billion came from recognizing the remaining deferred-income balance associated with Gilead's 2019 option, license, and collaboration agreement, or OLCA. The filing states that the balance was released after the cell-therapy wind-down and related amendments made continued deferral no longer justified; it also states that the OLCA remained in effect. The recognition increased reported revenue without creating an equivalent 2025 customer cash inflow or a renewable product franchise. Net profit of €320.9 million was therefore dominated by accounting release, while operating activities used €257.5 million of cash.

Historical results reinforce the lack of comparability. Collaboration revenue, Jyseleca commercialization and transfer effects, and research portfolios changed materially across 2021 through 2024. The 2024 group reported €275.6 million of supply and collaboration revenue and €74.1 million of net profit, while 2023 profit included economics connected with the Jyseleca transaction. Those results do not establish the earning power of GLPG3667 or of assets not yet acquired.

Interest income on approximately €3.0 billion of cash and investments can offset expenses, but it is a treasury return available to any owner of liquid securities, not a biotechnology moat. Residual royalties and earn-outs can create value without new commercial infrastructure, although their amount depends on another company's sales and contractual terms. Shareholders capture value only if future risk-adjusted drug cash flows plus residual assets exceed acquisition prices, clinical spending, wind-down costs, taxes, partner claims, and dilution. Employees, clinical sites, contract research and manufacturing organizations, licensors, regulators, and commercial partners receive payment before that residual is known.

Industry Structure and Capital Cycle

Biotechnology competition occurs first for assets and talent, then in trials, regulation, reimbursement, and the treated disease. Large pharmaceutical companies, specialist biotechnology firms, private capital, and well-funded platform companies can all bid for the same programs. Sellers possess strong bargaining power when an asset has credible human data or multiple interested buyers. Scarce clinical investigators, trial participants, manufacturing slots, and specialized employees can raise development cost. Contract research and manufacturing organizations are necessary suppliers but do not absorb the sponsor's scientific or regulatory risk.

Entry into early discovery is easy relative to producing an approved medicine. Intellectual property, biological uncertainty, trial design, enrollment, regulatory expertise, manufacturing reproducibility, and commercial access become cumulative barriers. Substitutes include approved therapies, competing mechanisms, surgery or supportive care, and future treatments that make a candidate clinically irrelevant. Even a technically successful drug may lack economic value if efficacy is undifferentiated, safety narrows use, or payers resist the price.

The capital cycle is pronounced. Positive scientific results and abundant financing attract simultaneous programs and high asset prices. Long development lead times mean competitors can reach the same target before demand and treatment standards are known. When funding contracts, asset prices may fall, but weak companies may sell programs whose underlying data or intellectual property is poor. Galapagos's liquidity gives it freedom to transact during constrained markets, yet that same visible cash can weaken negotiating discipline and invite pressure to complete a large deal.

GLPG3667 competes not only with drugs available today but with other immune and inflammatory therapies that may report data before it. The filings do not establish commercial differentiation. Cell-therapy experience and infrastructure could once have been an operating asset, but the decision to wind down after no viable financed divestiture proposal emerged is contrary evidence to claims that the platform retained readily monetizable value. Capital discipline, not pipeline count, is the relevant competitive test.

Sources and Durability of Competitive Advantage

At the cutoff, no durable product advantage was established. GLPG3667 has patents, know-how, and clinical work, but remains experimental. A patent excludes certain copying; it does not prove efficacy, safety, reimbursement, or superiority. The historical discovery organization generated programs and partnerships, yet management's decisions to discontinue discovery and wind down cell therapy show that organizational capability did not consistently produce an economically sustainable pipeline.

The strongest present asset is financial capacity. At December 31, 2025, cash and cash equivalents were €87.9 million and financial investments were €2.910 billion. That capacity can fund diligence, transactions, and trials without immediate dependence on capital markets. It can also be destroyed quickly through overpayment or serial development failures. Cash is an option to build an advantage, not the advantage itself.

Potential future advantages could arise from superior asset selection, trial execution, regulatory strategy, or partner structure. None is demonstrated merely by appointing executives with transaction experience. Gilead's relationship offers knowledge and possible collaboration pathways, while Gilead's 25.35% ownership at year-end 2025 and contractual rights may also complicate governance or economics. Durable advantage must ultimately be evidenced by clinical outcomes and retained rights relative to total capital deployed.

Operating System and Strategic Trade-offs

The operating system was being dismantled and rebuilt simultaneously. In January 2025, management proposed separating a business-development company from legacy operations and ending small-molecule discovery. In May, it abandoned the separation after regulatory and market developments and evaluated alternatives for cell therapy. In October, it announced an intended wind-down; after works-council processes, the board initiated that wind-down in January 2026. Repeated strategy changes can be rational responses to evidence, but they impose severance, impairment, distraction, and knowledge-loss costs.

The 2025 filings recorded a €228.1 million impairment of cell-therapy activities. The closure spans multiple sites and about 365 employees. Execution requires terminating contracts, protecting trial participants and data, preserving intellectual property, satisfying local labor processes, and retaining people needed for GLPG3667 and transactions. Expected savings are uncertain until facilities, vendors, leases, and personnel obligations are actually resolved.

For the future model, a small internal team must perform scientific diligence, negotiate rights, manage external development, and preserve accountability. Outsourcing trials and manufacturing converts some fixed costs to contracted costs but gives suppliers operational leverage and does not transfer sponsor liability. A larger rebuilt organization might execute more programs but recreate the fixed-cost base just dismantled. The useful measures are decision speed with analytical rigor, milestone achievement, clinical quality, cash spent per value-inflecting result, and rights retained—not employee count or number of signed deals.

Financial Resilience

Liquidity is exceptional relative to the current operating footprint. At December 31, 2025, Galapagos held €87.9 million in cash and cash equivalents and €2.910 billion in financial investments, with no credit lines. Total equity was €3.236 billion and total liabilities €170.7 million. Management stated that existing resources could fund operating and capital requirements for the coming years and in any event for at least twelve months under its assumptions.

That balance sheet absorbs near-term wind-down cost, GLPG3667 development, and transaction diligence. It does not make advanced drug development self-funding. Operating cash use was €257.5 million in 2025, and a transformative acquisition could commit billions before a product produces revenue. Foreign-exchange movements affect euro-reported resources because part of liquidity and spending is denominated in other currencies. Counterparty, interest-rate, and investment-duration choices also matter.

The primary resilience risk is discretionary capital allocation rather than refinancing. Management can turn liquid, auditable assets into uncertain clinical assets in one transaction. Legal obligations from closed programs, clinical follow-up, labor consultation, leases, and contracts may exceed initial estimates. Conversely, refusing every transaction preserves cash but leaves overhead and opportunity cost without an operating franchise. Financial strength lengthens the decision horizon; it does not resolve the scientific and strategic problem.

Capital Allocation and Shareholder Outcomes

Capital allocation is the thesis. The company must decide how much liquidity to reserve for wind-down and GLPG3667, how much to deploy into acquired or licensed programs, and whether excess capital should remain invested or be returned. The latest filing framed transformative business development as the priority. Because attractive clinical assets draw competitive bids, transaction price and retained economics can matter as much as scientific quality.

The January 2025 separation plan and its May reversal demonstrate that corporate structure itself consumed management attention without producing the intended outcome. The cell-therapy review also failed to produce a viable fully financed proposal before wind-down. These are relevant contrary facts: they show willingness to change course, but also uncertainty in converting assets into value. Future proposals should be judged against realistic probability-adjusted cash flows and the alternative of preserving or returning capital, not against a need to rebuild quickly.

Gilead held 25.35% of the company at December 31, 2025. Under a July 2025 royalty and waiver agreement, Gilead waived OLCA rights over cell-therapy research, allowing wind-down, licensing, divestment, or partnering, subject to a single-digit percentage of divestment revenue and single-digit royalties on certain net sales. This clarifies freedom to act but leaves an economic claim. Alfasigma earn-outs and Jyseleca royalties similarly belong in shareholder outcomes only when received or reliably measurable.

Per-share value creation requires that the risk-adjusted value of acquired rights and GLPG3667 exceed cash paid, future development spending, partner economics, and dilution. Reported net income from deferred-revenue release does not satisfy that test. Compensation should reward disciplined milestone creation and retained value, not deal volume or headline pipeline size.

Legal and Regulatory Exposure

GLPG3667 and any acquired program require authorization for clinical trials and, ultimately, marketing approval from the FDA, EMA, and other national authorities. Regulators can demand additional studies, impose holds, narrow labels, or reject applications. Trial sponsors must protect participants, report safety events, maintain data integrity, and comply with good clinical, laboratory, and manufacturing practices. A serious safety signal can impair the program, related mechanisms, and reputation at once.

Patent protection, licenses, freedom to operate, and trade-secret controls determine whether successful science produces exclusive economics. Challenges, expiry, compulsory rights, or third-party claims can reduce value. Outsourced research and manufacturing add quality, supply, privacy, anti-bribery, sanctions, and data-transfer exposure. Reimbursement and drug-pricing rules can limit commercial returns after approval.

Belgian corporate law and labor consultation govern the restructuring and proposed name change. The name change remained subject to shareholder approval after the evidence cutoff and should not be treated as completed. Gilead's ownership, board rights, OLCA, and cell-therapy waiver create related-party and governance considerations. The company also disclosed passive-foreign-investment-company implications for certain U.S. holders, but those investor-specific tax consequences do not alter operating value creation.

Conclusion, Uncertainties and Disconfirming Evidence

The established evidence describes a well-funded but economically unproven biotechnology company after the sale, discontinuation, or wind-down of most historical activities. Nearly €3.0 billion of cash and investments provides time and bargaining capacity. GLPG3667 supplies one continuing development program. Neither establishes a repeatable profit engine. Fiscal 2025's €320.9 million net profit is particularly misleading as an operating indicator because €1.069 billion of revenue was a non-recurring deferred-income release while operations consumed €257.5 million of cash.

The central thesis is conditional: management can create value only by buying or licensing assets below conservative risk-adjusted value, advancing them efficiently, and retaining enough commercial economics after suppliers, licensors, partners, payers, and regulators take their claims. Contrary evidence includes repeated strategic redirection, the failure to secure a viable cell-therapy transaction, the €228.1 million impairment, and reliance on a single remaining candidate. Interest income and residual Jyseleca cash flows are useful but are not an operating moat.

Adverse scenarios include GLPG3667 failure, an overpriced transformative acquisition, underestimated wind-down liabilities, loss of critical staff, unfavorable partner terms, clinical delay, or a broad biotechnology funding cycle that raises asset prices before development productivity improves. The thesis is invalidated if management deploys a material portion of liquidity without evidence-based hurdle rates; if acquired programs repeatedly lose value at clinical milestones; if overhead and restructuring consume cash without a credible pipeline; or if governance allows deal urgency to outrun owner economics. Success must be measured by probability-adjusted value and cash retained per share, not accounting revenue, corporate renaming, or pipeline quantity.

Business quality does not by itself establish investment attractiveness; valuation depends on the price paid and the expectations embedded in it.